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Diagnosis of Alzheimer’s disease is often missed or delayed
in clinical practice; thus, methods to improve early detection
would provide opportunities for early intervention, symp-
tomatic treatment, and improved patient function. Emerg-
ing data suggest that the disease process begins years
before clinical diagnostic confirmation. This paper reviews
current research focusing on methods for more specific and
sensitive early detection using measures of genetic risk for
Alzheimer’s disease and functional brain imaging. This
approach aims to identify patients in a presymptomatic
stage for early treatment to delay progressive cognitive
decline and disease onset.
dvances in medical technology have led to an
aging population. A major impact of this “age revolu-
tion” is a dramatic increase in persons afflicted with
Alzheimer’s disease (AD), the most common form of
late-life mental decline. In the United States, the disease
strikes approximately 4 million persons.1 Patients and
their caregivers suffer emotionally and bear a large pro-
portion of the economic burden, estimated to approach
$90 billion each year.2
Despite the prevalence of AD, the diagnosis is often
overlooked or mistaken.3 Barrett and associates4
reported that as few as 40% of primary care physicians
even knew that AD was the most common cause of
dementia in late life. Several types of diagnostic error
may occur, including incorrectly applying a dementia
diagnosis, positively diagnosing the disease when, in fact,
it is not present, or not recognizing dementia when it is
present. Such errors may result from a lack of attention
to cognitive functioning in routine medical examinations
and to misperceptions about the normal aging process.5
Early AD detection advances would not only offer
presymptomatic disease recognition but likely improve
diagnostic accuracy once cognitive impairment pro-
gresses to a dementia diagnosis.
Although no cure exists for AD, early disease detection
offers a number of potential benefits. Accurate differ-
ential diagnosis will identify patients with depression,
thyroid disease, or other treatable conditions. Once diag-
nosed, AD patients can then receive treatment for cog-
nitive losses as well as associated behavioral problems.
Drug treatments for cognitive impairment and non-
pharmacological and pharmacological treatments for
the behavioral problems associated with dementia can
also enhance quality of life.1
Several lines of research suggest that AD actually begins
years before its clinical manifestations are obvious.
Positron emission tomography (PET) studies of glucose
metabolism combined with genetic risk assessment show
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regional glucose abnormalities in middle-aged persons
with a genetic risk for AD.6 Studies of structural images
suggest that regional atrophy of hippocampus and other
medial temporal regions may be an early predictor of
future cognitive decline.7 Brain autopsy studies of nor-
mal aging and older persons with mild cognitive impair-
ment also indicate very early, preclinical accumulation of
neuritic plaques (NPs) and neurofibrillary tangles
(NFTs), the neuropathological hallmarks of AD, years
before a clinical diagnosis can be confirmed.8,9 Finally,
findings from a study of 93 nuns also support the notion
of subtle preclinical functional abnormalities. In that
study,10 a systemic assessment of these nuns’ early auto-
biographies (mean age 22 years) and their later (age 75-
95) cognitive performances found that low idea density
and lack of grammatical complexity in early life pre-
dicted low cognitive test scores in late life.
Identifying AD in a preclinical state before the condition
can be confirmed using consensus diagnostic criteria
also has several potential benefits.When early detection
assessments are negative, people with mild memory
complaints can be reassured that their forgetfulness
reflects a normal age-related change that probably will
not progress. In addition, many people would like to
know about a poor prognosis while still in a mildly
impaired state in order to plan their futures while men-
tal faculties remain. The most compelling argument for
preclinical detection strategies is to identify candidates
for antidementia treatments before extensive neuronal
death develops, since new antidementia treatments are
more likely to delay disease progression than to reverse
neuronal death. Patients with mild memory losses, who
are at risk for AD progression are ideal candidates for
antidementia interventions. Although current choliner-
gic treatments result in symptomatic rather than dis-
ease-altering or structural effects, it would certainly be of
interest to initiate treatments very early, as disease-mod-
ifying interventions emerge. Moreover, both the expense
and potential risks of treatment make it reasonable to
reserve treatment only for those people who are at the
greatest risk for developing the disease (Figure 1).
Our group has focused on early detection of AD by
combining measures of genetic risk and brain imaging.
This paper summarizes information on genetic discov-
eries and recent work using three different brain-imag-
ing approaches: measures of glucose metabolism using
fluorodeoxyglucose positron emission tomography
(FDG-PET) during mental rest, functional magnetic res-
onance imaging (fMRI) during memory performance
tasks, and in vivo imaging of NPs and NFTs using PET
and small molecule probes (Figure 2).
Genetic issues
Genetic studies have found an association between the
apolipoprotein E-4 (APOE-4) allele on chromosome 19
and the common form of AD that begins after age 60.11
APOE has three allelic variants (2, 3, and 4) and five
common genotypes (2/3, 3/3, 2/4, 3/4, and 4/4). The
APOE-4 allele has a dose-related effect on increasing
risk and lowering onset age for late-onset familial and
sporadic AD,11,12 while APOE-2 confers protection.13 The
APOE-4 allele is associated with decline in delayed
recall in older adults14 and is a strong predictor of future
242
Selected abbreviations and acronyms
AD Alzheimer’s disease
FDG-PET fluorodeoxyglucose positron emission tomography 
fMRI functional magnetic resonance imaging
MCI mild cognitive impairment 
PET positron emission tomography
SP senile plaque
NFT neurofibrillary tangle
NP neuritic plaque
Figure 1. Hypothetical decline curve for two patients with
Alzheimer’s disease, one who received treatment (dot-
ted line) another who did not (solid line). A major goal
of early detection is to intervene early in the course of
the disease, even in presymptomatic stages.
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cognitive decline in people with mild cognitive impair-
ment (MCI).15 However, APOE-4 may have only a mod-
est effect in predicting cognitive decline in many older
persons; thus,APOE genotype alone is not considered a
useful predictor in nondemented persons.16 The APOE
gene explains only 50% of the genetic variability in
AD,17 and investigators have searched for other linkage
regions18 and candidate genes.19,20
Combining PET scanning and genetic risk
measures
The discovery of the APOE-4 genetic risk for AD was
extremely helpful in our early AD detection efforts with
PET imaging. In 1995, our group first reported results
combining PET imaging and APOE genetic risk in peo-
ple with a family history of AD.21 We studied 12 nonde-
mented relatives with APOE-4 and 19 relatives without
APOE-4, and compared them with 7 probable AD
patients.“At-risk” subjects had mild memory complaints,
normal cognitive performance, and at least two relatives
with AD. Subjects with APOE-4 did not differ from
those without APOE-4 in mean age at exam (56.4 vs
55.5 years) or in neuropsychological performance. Pari-
etal metabolism was significantly lower and left-right
parietal asymmetry higher in at-risk subjects with
APOE-4 than in those without APOE-4. Patients with
dementia had significantly lower parietal metabolism
than did at-risk subjects with APOE-4. We concluded
that the APOE-4 allele was associated with reduced
cerebral parietal metabolism and increased asymmetry
in relatives at risk for AD.
The following year, Reiman and associates22 replicated
these results and extended them to other brain regions,
including temporal, prefrontal, and posterior cingulate in
a study of 11 APOE-4 homozygotes (4/4 genotype) and
22 APOE-3 homozygotes (3/3 genotype) of similar ages
to those in our own initial study (mid-fifties). They also
applied an automated image analysis method, wherein
metabolic reductions were standardized using three-
dimensional (3D) stereotactic surface projections from
FDG-PET scans of AD patients compared with controls.
The results from these two studies21,22 provided indepen-
dent confirmation of an association between genetic risk
and regional cerebral glucose hypometabolism.
More recently, our group23 performed FDG-PET scans
during mental rest on 65 middle-aged and older persons
(mean, SD: 67.3, 9.4 years; range 50-84 years) with mild
memory complaints or probable AD.24 Subjects (61 Cau-
casians, 3 Asians, and 1 Hispanic) were right-handed, in
the 50 to 84 year age range (mean, SD: 67.3, 9.4 years),
and recruited through newspaper ads and various refer-
rals. Of the 573 persons who volunteered because of
minor memory concerns (eg, difficulty remembering
names), 508 were excluded for a variety of reasons (eg,
medication use, concurrent medical illness). The 27 sub-
jects with age-associated memory impairment (AAMI)
and APOE-4 were matched according to age and edu-
cational level to 27 AAMI subjects without APOE-4.
The 11 AD patients were included as a comparison
group without regard to APOE status, since cerebral
metabolic patterns do not vary according to APOE
genotype in AD patients.25 Subject groups were similar
in mean age at examination, sex ratio, frequency of fam-
ily history of AD, dementia onset age within families,
and educational achievement level. Both verbal
(Buschke-Fuld)26 and visual (Benton)27 memory perfor-
mance scores were significantly lower in the demented
group but not significantly different between the two
nondemented groups (verbal: t=0.51, df=52, P=0.18;
visual: t=1.05, df=52, P=0.61).
Comparisons among the three subject groups (region
of interest [ROI] analysis) indicated the lowest meta-
bolic rates in the AD group, intermediate rates in the
nondemented group with APOE-4, and highest rates in
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Figure 2. Technological developments (blue) offer the potential
of identifying Alzheimer’s disease prior to the time
point when clinicians currently arrive at a clinical diag-
nosis. Combining various approaches is likely to improve
early diagnostic accuracy.
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the nondemented group without APOE-4.These differ-
ences were bilateral and significant (ANOVAs; df=2.59)
in inferior parietal (left hemisphere: F=9.2, P=0.0003;
right hemisphere: F=15.6, P<0.0001), posterior cingulate
(left: F=14.6, P<0.0001; right: F=17.7, P<0.0001), dorso-
lateral prefrontal (left: F=13.7, P<0.0001; right: F=5.6,
P=0.006), and inferior temporal regions (left: F=4.3,
P=0.018; right: F=3.4, P=0.040). Significant group differ-
ences present only in the left hemisphere were found in
the medial temporal (F=4.9, P=0.011) and superior tem-
poral (F=6.0, P=0.004) regions. Further comparisons
between the two nondemented groups indicated signif-
icantly lower metabolism in subjects with APOE-4 in
the inferior parietal region for both the right (t=2.6,
df=52, P=0.011) and left (t=2.2, df=52, P=0.035) hemi-
spheres compared with those without APOE-4. These
differences remained significant even if we eliminated
from the comparison the two subjects homozygous for
APOE-4. Statistical parametric mapping (SPM) analysis
comparing nondemented groups showed similar results
with APOE-4 subjects having significantly lower metab-
olism than those without APOE-4, particularly in the
left inferior parietal, lateral temporal, and posterior cin-
gulate regions.28 The peak voxels were in Brodmann’s
area 21 at (-68, -38, -16) with a secondary focus at (-70, -
48, 0).
Genetic risk and fMRI results 
Activation imaging during memory task performance
may reveal subtle alterations in brain function, perhaps
prior to the emergence of mild memory impairments.
This approach has been described as a “cognitive stress
test” for the brain.The approach is based on the hypoth-
esis that cognitive activity may uncover subtle brain
functional abnormalities not present during resting cog-
nitive states, similar to how the electrocardiogram stress
test reveals subtle cardiac abnormalities when the heart
is stressed from treadmill exercise. Functional MRI
(fMRI) provides measures of relative cerebral blood
flow (rCBF) during memory or other cognitive task per-
formance, and has the advantages of high resolution in
space and time and lack of radiation exposure.29 Thirty
middle-aged and older subjects with mild memory com-
plaints but normal memory performance received
APOE genotyping. The 14 subjects with the APOE-4
genetic risk for AD did not differ significantly from the
16 subjects without APOE-4 group in age, prior educa-
tional achievement, or rates of AD family history. Dur-
ing fMRI scanning on a 3-tesla unit, subjects performed
an unrelated paired associate learning task. Brain acti-
vation patterns were determined during both learning
and retrieval task periods and analyzed using both
between-group and within-subject approaches. Com-
pared with subjects without APOE-4, those at genetic
risk showed significantly greater magnitude and spatial
extent of rCBF during memory retrieval in regions
affected by AD: left medial temporal and bilateral pari-
etal and prefrontal. Longitudinal data indicated that
baseline brain activation correlated with verbal mem-
ory decline assessed 2 years later. Relative cerebral
blood flow responses to a memory challenge may reflect
compensatory cognitive efforts for emerging functional
deficits in people at genetic risk for AD. These results
suggest that combining brain activation and genetic risk
measures may provide information that eventually pre-
dicts future cognitive decline.
PET imaging of plaques 
and tangles in AD 
New research is under way to develop additional early
detection strategies with greater sensitivity and speci-
ficity, including studies aimed at imaging the neu-
ropathological hallmarks of AD. Intraneuronal NFTs and
extracellular β-amyloid-rich senile plaques (SPs) have
been implicated as central components of the pathogenic
cascade in AD, which highlights the importance of non-
invasive in vivo assessment of SP and NFT deposition.A
hydrophobic radiofluorinated derivative of 1,1-dicyano-
2-[6-(dimethylamino)naphthalen-2-yl]propene (FDDNP)
was used in conjunction with PET to determine the local-
ization and load of NFTs and SPs in the living brain of
AD patients (n=7) and controls (n=3).30 Fluorescence
microscopy also was used to determine SP and NFT
binding in AD brain specimens. Greater accumulation
and slower FDDNP clearance was observed in SP/NFT-
rich brain areas, particularly the hippocampus-amygdala-
entorhinal complex, but also temporal and parietal cortex
in advanced disease stages. In vitro fluorescence micro-
scropy showed excellent visualization of NFTs, SPs, and
diffuse amyloid in AD, matching results with thioflavin T
obtained in the same specimens. The availability of this
noninvasive technique may allow longitudinal evalua-
tion of SP and NFT deposition, permitting more accurate
diagnosis and evaluation of therapies.
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Diagnóstico precoz de la enfermedad de
Alzheimer: actualización acerca de la
combinación de mediciones genéticas y de
imágenes cerebrales
El diagnóstico de la enfermedad de Alzheimer
habitualmente es erróneo o se realiza tardía-
mente en la práctica clínica; por lo tanto, los
métodos que ayuden a la detección precoz facili-
tarán las opciones de una intervención oportuna,
de un tratamiento sintomático y de una mejoría
en el funcionamiento del paciente. La informa-
ción reciente sugiere que el proceso patológico
comienza años antes de la confirmación del diag-
nóstico clínico. Este artículo revisa la investiga-
ción actual, focalizándose en métodos para una
detección precoz más específica y sensible, a tra-
vés de mediciones del riesgo genético para la
enfermedad de Alzheimer y neuroimágenes cere-
brales funcionales. Esta aproximación ayuda a
identificar pacientes en una etapa presintomáti-
ca, para un tratamiento precoz que ayude a
retardar el deterioro cognitivo progresivo y la
aparición de la enfermedad. 
Le point sur l’association de l’évaluation
génétique et de l’imagerie cérébrale dans
le diagnostic précoce de la maladie
d’Alzheimer 
En pratique clinique, dans la maladie d’Alzheimer,
le diagnostic n’est pas toujours posé ou est sou-
vent retardé ; le développement de méthodes
diagnostiques précoces pourrait permettre une
prise en charge dès le début de la maladie, la
prescription d’un traitement symptomatique et
l’amélioration de l’état fonctionnel du patient.
Les nouvelles données dont nous disposons sug-
gèrent que le processus pathologique débute plu-
sieurs années avant que le diagnostic clinique ne
soit confirmé. Cet article concerne les recherches
en cours sur des techniques de diagnostic préco-
ce plus spécifiques et plus sensibles associant
l’évaluation du risque génétique de développer la
maladie et l’imagerie cérébrale. Cette approche a
pour objectif d’identifier les patients atteints à un
stade présymptomatique afin de les traiter pré-
cocement pour retarder l’apparition du déficit
cognitif et le début de la maladie. 
Conclusions
Evidence is emerging that suggests the eventual utility of
combining genetic risk and brain-imaging measures to
identify people with very mild memory loss that may be
progressive. With such surrogate markers, clinical trials
will be possible to determine efficacy of antidementia
treatments in presymptomatic stages.The goal is to delay
progressive memory loss upon dementia onset so that
older people can live longer lives with improved func-
tioning and mental capacities.❑
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